CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
淋巴瘤的细胞治疗
英文原题：Cellular therapy in lymphoma.
查看英文原题
Cellular therapy in lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CD19靶向嵌合抗原受体（CAR）T细胞疗法对高危B细胞非霍奇金淋巴瘤患者的自然病程和生存产生了巨大影响。伴随这一成功而来的是新医学领域的开拓，以及对毒性风险和缓解疗法、耐药机制、针对复发而开发的新型及下一代产品和策略，以及全球可及性和医疗经济学相关问题的研究。本文由国际淋巴瘤专家群体撰写，她们恰好也都是女性，对上述各个领域进行了综述，这些领域均与快速发展的CAR-T 细胞疗法密切相关。
展开英文摘要原文
CD19-directed chimeric antigen receptor (CAR) T-cell therapy has had a dramatic impact on the natural history and survival of patients with high-risk B-cell non-Hodgkin lymphoma. Accompanying this success has been the development of new fields of medicine and investigation into toxicity risks and mitigation therapies, mechanisms of resistance and the development of novel and next generation products and strategies in order to address relapse, and issues related to global access and health care economics.
This article is a survey of each of these areas as it pertains to the rapidly evolving field of CAR T-cell therapy, written by an International community of lymphoma experts, who also happen to be women.
论文信息
- 作者
- Sureda A、Lugtenburg PJ、Kersten MJ、Subklewe M、Spanjaart A、Shah NN、Kerbauy LN、Roddie C
- 第一作者单位
- Clinical Hematology Department, Institut Catala d'Oncologia - Hospitalet, Institut d'Investigatcions Biomediques de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain.Spain
- 通讯作者单位
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.United States
- 文献类型
- 综述
- 期刊
- Hematological oncology2024 Nov
- 原文标识
- PubMed 37382086 · DOI 10.1002/hon.3200